CN117677385A - 用于治疗肝病的培马贝特和/或托格列净 - Google Patents

用于治疗肝病的培马贝特和/或托格列净 Download PDF

Info

Publication number
CN117677385A
CN117677385A CN202280050095.0A CN202280050095A CN117677385A CN 117677385 A CN117677385 A CN 117677385A CN 202280050095 A CN202280050095 A CN 202280050095A CN 117677385 A CN117677385 A CN 117677385A
Authority
CN
China
Prior art keywords
patient
score
pharmaceutically acceptable
acceptable salt
nash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280050095.0A
Other languages
English (en)
Chinese (zh)
Inventor
金田升
大岛隆
S·S·潘德塞
谷川亮平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of CN117677385A publication Critical patent/CN117677385A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280050095.0A 2021-05-27 2022-05-25 用于治疗肝病的培马贝特和/或托格列净 Pending CN117677385A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194088P 2021-05-27 2021-05-27
US63/194,088 2021-05-27
PCT/IB2022/054867 WO2022249071A1 (en) 2021-05-27 2022-05-25 Pemafibrate and/or tofogliflozin for use in treating liver disease

Publications (1)

Publication Number Publication Date
CN117677385A true CN117677385A (zh) 2024-03-08

Family

ID=82020168

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280050095.0A Pending CN117677385A (zh) 2021-05-27 2022-05-25 用于治疗肝病的培马贝特和/或托格列净

Country Status (10)

Country Link
US (1) US20240277745A1 (cg-RX-API-DMAC10.html)
EP (1) EP4346809B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024520020A (cg-RX-API-DMAC10.html)
KR (1) KR20240013203A (cg-RX-API-DMAC10.html)
CN (1) CN117677385A (cg-RX-API-DMAC10.html)
AU (1) AU2022282651A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023024701A2 (cg-RX-API-DMAC10.html)
CA (1) CA3221073A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023013886A (cg-RX-API-DMAC10.html)
WO (1) WO2022249071A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024014524A1 (cg-RX-API-DMAC10.html) * 2022-07-15 2024-01-18
CN115991682A (zh) * 2023-03-21 2023-04-21 广州佳途科技股份有限公司 一种培马贝特-d4的制备方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
EP3569250B1 (en) * 2017-01-11 2025-04-30 Kowa Company, Ltd. Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease

Also Published As

Publication number Publication date
BR112023024701A2 (pt) 2024-02-15
AU2022282651A1 (en) 2023-12-07
KR20240013203A (ko) 2024-01-30
EP4346809A1 (en) 2024-04-10
CA3221073A1 (en) 2022-12-01
MX2023013886A (es) 2024-04-19
JP2024520020A (ja) 2024-05-21
WO2022249071A1 (en) 2022-12-01
EP4346809B1 (en) 2026-07-15
US20240277745A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
US20220257591A1 (en) Methods for Treating Visceral Fat Conditions
IL268316A (en) Pharmacological preparations for combined treatment
Bensimon et al. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis
CN119838000A (zh) 用于药物治疗的司美鲁肽
US20220202882A1 (en) Effect of combination of bifidobacterium and berberine on pre-diabetes and type 2 diabetes
US20250262225A1 (en) Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
US20220265614A1 (en) Treatment comprising fxr agonists
US20240277745A1 (en) Pemafibrate and/or tofogliflozin for use in treating liver disease
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
US20190161483A1 (en) Methods for using fxr agonists
Punzi et al. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial
US20220347190A1 (en) Treatment comprising fxr agonists
CA3034956C (en) TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE
US20250302798A1 (en) Sting inhibitors and use thereof
JP2022523464A (ja) 脂肪性肝疾患を処置するためのモノアセチルジアシルグリセロール化合物を含む組成物
CN120789063A (zh) 一种药物组合物、制剂及其制备方法和应用
HK40012462B (en) Treatment of nonalcoholic fatty liver disease
HK40012462A (en) Treatment of nonalcoholic fatty liver disease
KR20210020788A (ko) 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
Adis Editors Xenical: generic name: orlistat
Capsules NDA 203858 Lomitapide Mesylate Capsules 5 mg, 10 mg, 20 mg Applicant: Aegerion Pharmaceuticals, Inc. Endocrinologic and Metabolic Drugs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination